<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112343</url>
  </required_header>
  <id_info>
    <org_study_id>2016-08-006-001</org_study_id>
    <nct_id>NCT03112343</nct_id>
  </id_info>
  <brief_title>Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment</brief_title>
  <acronym>ICT</acronym>
  <official_title>An Information and Communication Technology-based Centralized Clinical Trial to Determine the Efficacy and Safety of Insulin Dose Adjustment Education Based on a Smartphone Personal Health Record Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Trade, Industry &amp; Energy, Republic of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea Evaluation Institute of Industrial Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daegu Metropolitan City, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICT Clinical Trial Coordination Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24-week, open-label, randomized, multi-center trial conducted in three tertiary
      hospitals. There are three follow-up measures; at baseline, post-intervention at Week 12, and
      Week 24. Subjects are diagnosed as type 1 DM, type 2 DM, and/or post-transplant DM, and
      initiate or currently use insulin therapy. After the given education on insulin dose
      titration and prevention for hypoglycemia and 1 week of run-in period, subjects are
      randomized in a 1:1 ratio to either the ICT-based intervention group or the conventional
      intervention group. Subjects in conventional intervention group will save and send their
      health information to the server via the PHR app, whereas those in ICT-based intervention
      group have additional algorithm-based feedback messages. The health information includes
      levels of blood glucose, insulin dose, details on hypoglycemia, food diary, and number of
      steps. The primary outcome will be the proportion of patients who reach an optimal insulin
      dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled
      clinic visits.

      This study is based upon work supported by the Ministry of Trade, Industry &amp; Energy (MOTIE,
      Korea) under Industrial Technology Innovation Program (No. 10059066, 'Establishment of ICT
      Clinical Trial System and Foundation for Industrialization.&quot;)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 24-week, open, randomized, multi-center ICT-based clinical trial conducted in three
      different hospitals including Samsung Medical Center, Kangbuk Samsung Hospital, and Samsung
      Changwon Hospital. There are three follow-up measures; at baseline, post-intervention at Week
      12, and Week 24. Subjects diagnosed as T1DM, T2DM, and/or post-transplant DM who initiate or
      currently use insulin therapy will be given education on insulin injection, dose adjustment,
      and prevention for hypoglycemia and provided at-home measurement device at Visit 1 for
      screening. Subjects will receive instructions to check daily glucose levels by home glucose
      meter, to record insulin regimen and dose, the hypoglycemia diary if blood glucose &lt;70 mg/dL
      or a hypoglycemic event occurs in the apps, and to synchronize data for automatically
      transferring to system. Subjects who synchronized their information more than once during 1
      week of run-in period will be selected into clinical trial and randomly assigned to either
      ICT-based intervention group or conventional intervention group at a ratio of 1:1. After the
      randomization, at Week 1, diabetes educators provide telephone counselling for re-instructing
      insulin dose adjustment and for re-confirming their use of at-home measurement device and PHR
      apps at Visit 2 (televisit). Subjects in ICT-based intervention group will have
      algorithm-based feedback messages when their glucose levels are out of ranges, in addition to
      recording, saving and sending their data to the server via the PHR app, and those in
      conventional intervention group will only record, save and send their data to the server via
      the PHR app. Investigators examine the saved health information such as levels of blood
      glucose, insulin dose, details on hypoglycemia recorded in hypoglycemia diary, food diary,
      and number of steps transferred through PHR apps. At each clinical visit, anthropometric
      parameters, current medication use including types of insulin, insulin dose, and other
      glucose-lowering agents, vital signs, body composition, and questionnaire for satisfaction
      investigation are examined face-to-face, and blood tests are performed. The unscheduled visit
      to clinic could be applied if a subject has one or more severe hypoglycemia (requiring other
      help for recovery) during the study period, or hypoglycemia (&lt;70 mg/dL) twice or more times
      per week, or fasting blood glucose &gt;200 mg/dL three or more times in the morning, and wants
      to see a doctor during Week 1-12. The unscheduled visit to clinic is also allowed to the
      subjects who have difficulty in insulin dose adjustment despite of two or more unscheduled
      tele-visit. However, even if this criterion does not apply, patients who initiate insulin or
      change their regimen (eg, from basal insulin once daily to premixed insulin or multiple dose
      insulin injections) will be allowed to have additional planned doctor visits prior to Visit
      3, which is not included in the unscheduled visit, but will be evaluated as scheduled
      additional visit. The primary outcome will be the proportion of patients who reach an optimal
      insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or
      unscheduled clinic visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized in a 1:1 ratio to either the information and communication technology(ICT)-based intervention group or the conventional intervention group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients who reach his/her optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits.</measure>
    <time_frame>Week 12</time_frame>
    <description>Reaching optimal insulin dose: A.For a patient who uses basal insulin only or basal insulin with pre-meal rapid-acting insulin once per day,1)3 or more fasting blood glucose(FBG) values in the morning within the target range(80-130mg/dL or 100-140 mg/dL) during Week12,2)no nocturnal(11pm-7am) or pre-breakfast hypoglycemia(&lt;70mg/dL) during Week12,3)variation of basal insulin dose (the difference between the highest and lowest basal insulin dose) of &lt;10% of mean total basal insulin dose during Week12. B.For a patient who uses MDI at least twice per day, the criteria A plus 4)3 or more days in which correction dose premeal insulin is required less than 3times per day during the Week12,5) no daytime(7am-11pm) hypoglycemia during Week12. C.For a patient who uses premixed insulin or NPH,1)3 or more FBG values in the morning and evening within the target range during Week 12,2) no nocturnal or pre-breakfast hypoglycemia during Week12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients who reach HbA1c &lt;7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>the proportion of patients who reach HbA1c &lt;7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients who reach HbA1c &lt;7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>the proportion of patients who reach HbA1c &lt;7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean fasting blood glucose values for three consecutive days prior to Week 12 and Week 24</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>mean fasting blood glucose values for three consecutive days prior to Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of HbA1c at Week 12 and Week 24</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>levels of HbA1c at Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile at Week 12 and Week 24</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>lipid profile at Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients having hypoglycemia (total, asymptomatic, daytime, nighttime, severe hypoglycemia, and coma/convulsions) at Week 12 and Week 24</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>the proportion of patients having hypoglycemia (total, asymptomatic, daytime, nighttime, severe hypoglycemia, and coma/convulsions) at Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of steps during Week 1-12 and Week 13-24</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>the number of steps during Week 1-12 and Week 13-24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recorded exchange unit by food group</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>recorded exchange unit by food group (grains, meats and protein, fruits, vegetables, dairy, and fats and oils) in each breakfast, lunch, and dinner on 3-day food diary at Week 12 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily insulin dose</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>daily insulin dose at Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>blood pressure at Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>body weight at Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lean body mass</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>lean body mass at Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fat mass</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>fat mass at Week 12 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction evaluation by questionnaire for ICT-based centralized clinical trial monitoring</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>Satisfaction evaluation by questionnaire for ICT-based centralized clinical trial monitoring at Week 12 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction evaluation by DTSQ</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>Satisfaction evaluation by DTSQ at Week 12 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of telephone counselling by diabetes educators</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>the number of telephone counselling by diabetes educators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of self-monitoring blood glucose measurements</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>the number of self-monitoring blood glucose measurements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Insulin Hypoglycemia</condition>
  <condition>Insulin-dependent Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>ICT-based intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional intervention group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Algorithm-based feedback messages</intervention_name>
    <description>ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention</description>
    <arm_group_label>ICT-based intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Personal Health Record</intervention_name>
    <description>Subjects will save and send their health information to the server via the personal health record app</description>
    <arm_group_label>ICT-based intervention</arm_group_label>
    <arm_group_label>Conventional intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. age between 18-69 years

          2. diagnosis of T1DM, T2DM, and/or post-transplant DM (Post-transplant DM includes both
             diagnosed T1DM or T2DM before organ transplantation and first diagnosed DM after organ
             transplantation)

          3. initiation or current use of insulin therapy including once-daily basal insulin
             (including basal insulin only or basal insulin plus rapid-acting insulin), premixed
             insulin, or NPH)

          4. most recent hemoglobin A1c (HbA1c) â‰¥7.0% based on the National Glycohemoglobin
             Standardization Program (NGSP) at least 3 months prior to participation (recent HbA1c
             values measured &lt;3 months prior to screening are permitted.)

          5. available to use smartphone and wireless internet

          6. Voluntarily write consent to participate in the trial

        Exclusion criteria

          1. on insulin pump

          2. history of alcohol or drug abuse 1 year prior to participation

          3. history of psychological disorder (e.g., schizophrenia, depression, or bipolar
             disorder)

          4. history of severe visual or hearing impairment

          5. pregnant

          6. any condition, in the investigator's opinion, not suitable for enrollment eligibility.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Man Jin, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang-Man Jin, MD PhD</last_name>
    <phone>+82-2-3410-0271</phone>
    <email>sangman.jin@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gyuri Kim, MD PhD</last_name>
    <phone>+82-10-8752-5513</phone>
    <email>star4021@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Man Jin, MD PhD</last_name>
      <phone>+82-2-3410-0271</phone>
      <email>sangman.jin@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Sang-Man Jin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Sang-Man Jin</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>ICT based clinical trial</keyword>
  <keyword>Contract research organization (CRO)</keyword>
  <keyword>eCRF</keyword>
  <keyword>Joint Electronic-institutional review board (eIRB)</keyword>
  <keyword>Centralized monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

